drugset / Trial / NCT05238948
CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects
NaSequentialOpen-labelSupportive care
Summary
This will be a Phase 1, open-label, 1-sequence crossover drug-drug-interaction study in 16 healthy male subjects to assess the effect of single and multiple doses of CKD-506 on the single-dose PK of oral midazolam. Midazolam will be used as a cytochrome P450 (CYP)3A4 substrate in this study.
Timeline
- Start
- 2022-02-28
- Primary completion
- 2022-04-29
- Completion
- 2022-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CKD-506 | Unknown | — | — |
| Subject | Midazolam | Small molecule | — | — |
Indications
No indication recorded.